Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors

G. Varuni Kondagunta,Jennifer Bacik,Lawrence Schwartz,Joel Sheinfeld,Dean Bajorin,Jacqueline Vuky, Stephanie Marion,Madhu Mazumdar,George J. Bosl,Robert J. Motzer

Investigational New Drugs（2004）

引用 13|浏览18

暂无评分

摘要

Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m 2 /day on days 1–5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.

查看译文

关键词

temozolomide,germ cell tumor,nonseminoma,cisplatin-refractory,phase II

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要